Thermo Fisher: A Long-Term Owner's Perspective

Cost structure and dependencies. In 2025, the company's costs and expenses included product costs of $13.405 billion, service costs of $12.913 billion, selling, general and administrative expenses of $8.732 billion, R&D expenses of $1.397 billion, and operating income of $7.746 billion. This structure shows two things. The company must keep investing in manufacturing, service networks, and R&D, so it is unlike a software-style asset-light business. It also retains meaningful expense absorption and profit conversion capacity, so it is unlike a heavy-chemical low-gross-margin model. On customers, I did not see a clear public disclosure indicating major dependence on any single customer in the pages I checked. 【Inference】 Given the broad distribution of its service markets, customer concentration risk should be lower than that of most single-track equipment vendors, although this judgment should still be treated as an inference rather than a verified explicit fact.

Is this a business I can understand? Yes. Its essence can be summarized as providing "high cost-of-failure" infrastructure for the global scientific research and pharmaceutical value chain. Customers buy more than hardware. They buy validated outcomes, reliable supply, compliant processes, operating support with lower downtime costs, and the ability to make as few mistakes as possible. If the stock market closed for five years, I would be willing to own this business, but I would not be willing to own it at any price. Business understandability score: 4.5/5.

Industry and competitive structure. 【Fact】 Strong competitors in the same ecosystem include at least Danaher, Agilent, and Waters. Danaher's 2025 sales were about $24.568 billion. Agilent's fiscal 2025 net revenue was about $6.948 billion. Waters' 2025 net sales were about $3.165 billion. Agilent describes itself as a global leader in life sciences, diagnostics, and applied markets. Waters emphasizes its position in regulated, high-throughput applications and says more than 70% of its annual revenue is recurring. 【Inference】 TMO leads in breadth, channels, and platform completeness. Danaher is extremely strong in bioprocessing and parts of diagnostics. Waters is more specialized in chromatography/mass spectrometry and regulated analytical workflows. Agilent is steady in applied laboratories and the consumables-services ecosystem. This is a good industry with durable demand and real competition, where companies must keep innovating and executing on service to protect their moats.

Industry attractiveness judgment. Long-term demand comes from drug discovery, bioprocessing, quality control, clinical testing, food and environmental safety. These needs are plain, durable, and hard to eliminate. The industry will be disturbed by technology refresh cycles and customer capital spending cycles, yet a single shift in consumer habits is unlikely to disrupt it. The real risks are customer budget contraction, technology substitution that causes some product lines to lose advantages, and regulatory and trade environments that distort margins. Industry attractiveness score: 4/5.

Moat and Management

Does a moat exist? Answer: yes, but not every edge is equally solid. Brand advantage: yes. The brand portfolio of Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Patheon, PPD, and others is itself the "default candidate list" in laboratory procurement and quality systems. Scale advantage: strong. TMO is a broad-spectrum scientific infrastructure platform, with revenue at the $44.5 billion level and coverage across many markets and customer groups worldwide. Switching costs: relatively strong. In clinical settings, regulated analysis, GxP manufacturing, bioprocessing, method validation, and laboratory SOPs, switching equipment, reagents, service providers, and outsourcing partners essentially means revalidation, retraining, renewed downtime risk, and renewed compliance risk. Channel advantage: strong. Fisher Scientific and the global service network allow it to sell high-value equipment while also capturing daily procurement traffic. Patent/regulatory barriers: moderately strong. A single patent may be replaceable on its own, yet the combined effect of "validated processes + compliance systems + installed base + service response" is not easy to replicate. Network effects: weak. This is not a typical platform network-effect business. Data advantage: moderate. Customer workflow accumulation can improve application support and service, but data does not create the overwhelming advantage seen in internet platforms. Corporate culture and operating capability: strong. TMO's operating capability and M&A integration capability have long been among its most valuable "intangible assets."

Is the moat widening, stable, or narrowing? 【View】 My judgment is "overall stable, with some links widening." The widening parts are mainly biopharma services, laboratory supply-chain integration, workflow embedding, and cross-category cross-selling. The parts that are not obviously widening are generic instruments themselves, because instruments still face technological catch-up and capital spending cycles. In Q1 2026, management also mentioned that margins were affected by business mix, strategic investments, and tariffs and foreign exchange, showing that even a strong platform cannot sleepwalk through every environment. Moat strength score: 4/5.

Does it have pricing power? Yes, within limits. 【Fact】 From 2023 to 2025, company revenue rose from $42.857 billion to $44.556 billion, while the operating margin recovered from about 16.0% to about 17.4%. In Q1 2026, management also disclosed that tariffs and related foreign-exchange effects weighed on margins, mainly offset by productivity improvements. 【Inference】 This shows TMO has some ability to raise prices and pass through costs, while its economics still look more like a business that can partially absorb inflation than a monopoly that can pass every cost increase to customers.

Can it remain profitable in an economic downturn? Probably yes. 【Fact】 In 2023, during the post-pandemic industry destocking period, TMO still generated $42.857 billion of revenue, $6.859 billion of operating income, and $5.995 billion of net income attributable to Thermo Fisher. Profits continued to recover in 2024 and 2025. 【Inference】 It is a company that will be affected by the cycle, but is not easy to push into losses.

Is management trustworthy? Marc Casper has served as CEO since 2009 and has long led the company's expansion and M&A integration. The 2026 proxy shows that management incentives do not simply target EPS. They include organic revenue growth, free cash flow, strategic goals, and long-term shareholder alignment in the assessment framework. The CEO held 449,661 shares of company stock. The company's CEO ownership guideline is 6x base salary, and after RSUs vest, he must continue to hold at least 50% of net shares received for two years. 【Fact】 This at least shows that "talking about long-termism" and "institutionally reinforcing long-termism" are matched.

Is capital allocation rational? My assessment is "good overall, but vigilance is necessary." 【Fact】 In its 10-K, the company clearly states that the priority order for capital deployment is M&A first, then buybacks and dividends. At the end of 2025, cash and short-term investments totaled about $10.105 billion, and total debt was $39.384 billion. In Q1 2026, total debt rose again to $43.161 billion, while cash basically fell to $3.254 billion. Meanwhile, at the end of 2025, goodwill plus acquisition-related intangible assets totaled about $65.2 billion. 【Inference】 Over the past decade-plus, this "M&A + integration + platform amplification" model has indeed created value. But looking forward from today, it also makes the investment thesis depend heavily on "future acquisitions remain high quality," so capital allocation is a double-edged sword.

Management and capital allocation score: 4/5. The deduction reflects the balance sheet's already high dependence on acquisitions, rather than integrity concerns.

Financial Quality and Owner Earnings

Start with a key table from a "long-term owner" perspective. Below, I first show the SEC original-reporting anchor years that I have checked item by item. I separately add the latest 2023-2025 changes after the table. All amounts are in billions of U.S. dollars, and share count is diluted weighted-average shares.

Table notes: 2018-2020 data come from the 2020 10-K. 2021 data come from the 2021 10-K. 2022 data come from the 2022 10-K. 2025 revenue, net income, and share count come from the 2025 10-K. Capital expenditures come from 2025 segment and cash flow disclosures. 2025 free cash flow is estimated using the simplified method of "operating cash flow minus capital expenditures." The 2025 proxy separately disclosed non-GAAP free cash flow of $6.337 billion, close to this simplified estimate.

How should this table be interpreted? First, from 2018 to 2025, TMO's revenue CAGR was about 9%, net income attributable to Thermo Fisher CAGR was about 12.5%, and simple free cash flow CAGR was about 7.5%. This is a typical compounding platform with good growth and meaningful capital needs. Second, in 2021-2022, margins were elevated due to pandemic-related demand and acquisitions. The 16%-17% operating margin in 2023-2025 is closer to the "normal margin range" I think should be used for long-term valuation. Third, diluted shares declined from about 406 million in 2018 to about 378 million in 2025, which shows that buybacks have indeed improved per-share value over the long term, rather than merely decorating headline scale growth.

Latest financial quality. 【Fact】 In 2025, the company had revenue of $44.556 billion, operating income of $7.746 billion, and net income attributable to Thermo Fisher of $6.704 billion. In Q1 2026, revenue was $11.005 billion, operating income was $1.863 billion, net income attributable to Thermo Fisher was $1.651 billion, operating cash flow was $1.192 billion, and capital expenditures were $0.376 billion. 【Inference】 Cash flow improvement in the latest quarter indicates that profits have not obviously become "hollowed out." But tariffs and foreign exchange pressured Q1 margins, reminding us not to extrapolate post-2025 earnings too smoothly or optimistically.

Are profits real cash profits, or accounting profits? I lean toward judging them as "mainly real cash profits." The reasons are: first, in most years, TMO's operating cash flow has been significantly higher than net income; second, 2025 free cash flow calculated under a simplified method was about $6.293 billion, quite close to net income attributable to Thermo Fisher of $6.704 billion, indicating healthy cash conversion; third, PricewaterhouseCoopers has served as the external auditor since 2002, and I did not see obvious abnormal audit opinions in the pages I checked. 【But one caveat is necessary:】 Because the company depends heavily on acquisitions, GAAP net income includes substantial amortization of acquisition-related intangible assets. Therefore, "accounting profit quality is good" does not mean "every acquisition is economically correct."

Is the balance sheet sound? At the end of 2025, the company had about $10.105 billion of cash and short-term investments and about $39.384 billion of total debt. By Q1 2026, cash and short-term investments had fallen to about $3.256 billion, and total debt had risen to $43.161 billion. Using the latest net debt and approximate LTM EBITDA as a rough estimate, net debt/EBITDA is around 3.7x. Using the 2025 basis, net debt/EBITDA is closer to 2.8x. 2025 EBIT covered interest expense by roughly 5.5x. 【View】 This balance sheet is manageable, yet far from "traveling light." For conservative investors, this leverage level requires continuous monitoring of the priorities among M&A, buybacks, and deleveraging.

Owner Earnings estimate. I use a conservative approach, rather than the most generous one. 【Fact】 2025 net income attributable to Thermo Fisher was $6.704 billion. 【Assumption】 I add back about $1.156 billion of depreciation and about $310 million of stock-based compensation. For amortization of acquisition-related intangible assets, I conservatively add back only half, treating it as about $865 million, because while this type of amortization is non-cash, it is too optimistic to treat 100% of it as "freely distributable cash" in a company that relies on acquisitions over the long term. 【Assumption】 Maintenance capital expenditures are estimated at $1.2 billion, below total capital expenditures but not using an overly low assumption. I then deduct about $150 million of normalized working-capital use. On this basis, conservative Owner Earnings are about $7.69 billion. At the current market capitalization of about $167.2 billion, the market valuation is roughly 21.8x conservative Owner Earnings. If the $6.337 billion of free cash flow disclosed in the 2025 proxy is used as a stricter measure, the current market capitalization corresponds to about 26.4x FCF.

Owner Earnings conclusion. 【View】 TMO's real earning power is strong, while its capital expenditures and acquisition dependence keep it away from a purely asset-light profile with naturally explosive cash flow. Its most important strength is that long-term cash flow is solid and profit has not clearly diverged from cash. Its most important reservation is that if you ignore the "economic cost" behind acquisition amortization, you will overestimate its distributable cash flow.

Valuation and Margin of Safety

Start with the conclusion: the current price is closer to "reasonable but somewhat expensive" than to "obviously cheap." As of May 22, 2026, TMO traded at about $448.28 per share, with a market capitalization of about $167.2 billion and a static P/E of about 24.6x. Based on 2025 non-GAAP free cash flow of $6.337 billion, the simple FCF yield is about 3.8%. Based on my more conservative Owner Earnings of $7.69 billion, the Owner Earnings yield is about 4.6%. The contemporaneous U.S. 10-year Treasury yield was about 4.57%. 【Inference】 This means that buying TMO today is not "picking up a cheap cash cow." It is prepaying part of the price for future mid-single-digit growth and long-term high-quality operations.

Discounted Owner Earnings method. The following valuation uses an equity value method, meaning the cash flow being discounted is Owner Earnings, which is already "shareholder cash flow after interest." Therefore, debt is not deducted again. The range differences mainly come from the Owner Earnings starting point and growth/discount-rate assumptions.

Valuation explanation: In my framework, the current $448 price roughly falls in the lower half of the base valuation range, materially above the conservative valuation range, but not absurdly expensive. Therefore, it looks more like "a quality company at a reasonable price" than "a quality company on a clearance sale."

Relative valuation method. The table below uses, as much as possible, official financial reports I have checked and the latest market prices. Items marked "estimated" in EV/Sales, P/FCF, and EV/EBITDA are simplified calculations based on market capitalization, debt, cash, and cash flow/depreciation and amortization. PB is of limited use for an acquisition-driven company with heavy intangible assets, so I focus on P/E, EV/Sales, P/FCF, and EV/EBITDA.

How should this table be read? TMO is expensive on an absolute basis and still reasonable relative to top-tier peers. Compared with Danaher, TMO has a lower P/E, while its simplified P/FCF is slightly higher, indicating that the market views TMO as a more stable, though not necessarily cheaper, compounding platform. Waters is materially more expensive because it is more focused and has higher recurring revenue in regulated applications. 【View】 If one looks only at peer valuation, TMO can be called "reasonable." If one uses the long-term owner's standard of requiring a "margin of safety," it still cannot be called cheap.

Asset value or liquidation value method. This is unfriendly to TMO. At the end of 2025, the company had total assets of about $110.343 billion, including goodwill of $49.362 billion and acquisition-related intangible assets of $15.838 billion, for a combined $65.199 billion. Shareholders' equity was about $53.407 billion. In other words, on a book basis, the company's tangible net assets are effectively negative. This does not mean TMO is about to be liquidated. It means your downside protection comes from future cash flow, not asset liquidation value. For conservative investors, this point is very important.

Fair buy, hold, and overvaluation ranges. Based on the three methods above, I give the following price bands:

• Conservative intrinsic value range: $340-$385

• Fair intrinsic value range: $440-$495

• Bull intrinsic value range: $545-$615

• Ideal buy price range: $320-$380, corresponding to a sufficient discount to base valuation or a price close to the upper end of conservative intrinsic value.

• Acceptable hold price range: $380-$470, meaning existing holders do not necessarily need to sell, while new capital may not have highly favorable odds.

• Clearly overvalued price range: above $530, at which point future returns would increasingly depend on sustained high growth and a sustained high multiple. At the current $448.28 price, TMO is at a clear premium to conservative intrinsic value and roughly reasonable relative to base intrinsic value.

Margin of safety conclusion: insufficient.

Risks, Comparisons, and Final Conclusion

Most important risks. First, M&A and capital allocation risk. TMO's past success came to a large extent from M&A integration, and the large goodwill and acquisition-related intangible asset balance at the end of 2025 indicates that if future acquisition returns decline, shareholders will feel a triple hit from slower growth, impairments, and valuation compression. Second, external environment and margin risk. In Q1 2026, management explicitly said tariffs and related foreign-exchange effects dragged on margins, showing that the macro and trade environment can directly affect near-term earnings. Third, valuation risk. Even if the company remains a good company, if the market is only willing to pay 18x-20x Owner Earnings rather than today's implied higher multiple, long-term returns will be consumed. Fourth, leverage risk. Debt rose in Q1 while cash declined significantly. This is manageable, yet it raises the monitoring burden for balanced but conservative investors. Fifth, industry technology substitution and budget-cycle risk. Scientific tools and laboratory equipment are not perpetual monopolies. Customers' capital spending, policy budgets, and changes in technological direction can all cause certain product lines to age.

The strongest opposing view. "You see a great company; the short case sees a company already well understood and fully priced by the market. Its earnings quality is good, but the balance sheet is full of book value from past acquisitions. Its cash flow is stable, but the current free cash flow yield is roughly similar to the 10-year Treasury yield. In other words, TMO is not a bad company. It may simply be a company that cannot deliver a good enough return." I think this is the most damaging opposing logic against TMO, and it is not absurd.

What facts would overturn my investment judgment? If the following happen, I would admit that the original judgment needs to be rewritten: First, organic growth is materially below the industry for several consecutive quarters while the operating margin falls below the mid-to-high-teens range that I regard as normalized. Second, management continues to pursue large acquisitions while per-share free cash flow and ROIC decline rather than rise. Third, net debt/EBITDA stays in a higher range for a long time without a clear deleveraging path. Fourth, key brands/platforms show clear share loss in important workflows.

Compared with other opportunities, does it deserve capital? Compared with Danaher, TMO is somewhat cheaper while still expensive. Compared with a broad index, TMO's advantages are business quality and understandability, while its disadvantages are single-company risk and acquisition dependence. Compared with the 10-year Treasury yield of 4.57%, TMO's simple FCF yield is even lower, and the conservative Owner Earnings yield is only barely comparable. Therefore, the reason to buy it can only be "believing it can grow steadily over the next decade and keep raising cash flow per share over the long run." Today's cash return alone is not attractive enough. 【View】 If you could hold only five assets, TMO is qualified to enter the "excellent candidate list," though at the current price, I do not think it automatically enters the top five.

Checklist.

Checklist basis: 2025 adjusted ROIC of 11.3%, free cash flow as a core assessment metric, CEO share ownership and holding requirements, and the comparison between current valuation and Treasury yield are the main factual bases for the conclusions above.

【Final Rating】 Watch

【One-Sentence Investment Thesis】 TMO is a high-quality scientific infrastructure platform that can be held for the long term, but buying at the current price makes returns depend more on sustained future execution than on a sufficiently wide margin of safety today.

【Core Bull Case】 TMO's platform breadth, brand portfolio, global channels, and service network mean it does more than sell equipment; it embeds itself in customer workflows. Cash flow has been solid over the long term, and profit has not clearly diverged from cash. Management incentives put organic growth, free cash flow, and long-term value creation at the center. Q1 2026 shows that the company can still recover growth after industry normalization.

【Core Bear Case】 The current valuation is not cheap, and the margin of safety is not obvious. The balance sheet is highly dependent on acquisitions, with goodwill and acquisition-related intangible assets accounting for too much. Q1 2026 already showed real pressure on margins from tariffs and foreign exchange. If growth falls short of expectations while valuation multiples compress, long-term returns will be significantly squeezed.

【Key Assumptions】 Owner Earnings can maintain roughly mid-single-digit growth over the next decade. Acquisitions continue to create positive per-share value rather than merely expanding scale. Net debt will not continue to rise systematically. Core brands and workflow positions do not suffer structural weakening.

【Fair Buy Price】 $320-$380. Rationale: it roughly corresponds to the middle-to-upper part of my conservative intrinsic value range, or to a more meaningful discount to base intrinsic value.

【Target Holding Period】 At least 5 years, preferably more than 10 years. If this investment works, it will be because of compounding and capital allocation, not the sentiment swings of two or three quarters.

【Expected Annualized Return】 Conservative scenario: 3%-5%; base scenario: 6%-8%; bull scenario: 9%-11%. This is a rough range judgment based on current valuation, conservative Owner Earnings yield, future growth assumptions, and valuation mean reversion. It is not a price forecast.

【Maximum Loss Risk】 If growth stalls over the next two or three years, acquisition returns deteriorate, leverage remains high, and the market re-rates the stock down to around 18x Owner Earnings, the share price could face a 30%-40% medium- to long-term downside risk. In an extreme stress scenario, if asset impairments and a significant industry downturn are added, losses could be larger.

【Tracking Indicators】 Going forward, I will focus on tracking: organic revenue growth, operating margin, free cash flow, simple FCF/net income conversion, net debt/EBITDA, acquisition scale and post-acquisition ROIC, share count changes, growth quality in Biopharma Services, tariff/foreign-exchange effects on margins, and whether R&D and service investment are sufficient to maintain competitiveness.

【Signals that Trigger Reassessment】 Organic growth misses expectations for multiple consecutive quarters. Operating margin steps down materially. Free cash flow remains below net income. Goodwill continues to rise significantly after acquisitions, but per-share cash flow does not grow. Net debt/EBITDA remains high for a long time. Core workflow share is lost.

【Final Recommendation】 Calmly stated, TMO is an excellent business worthy of long-term research and long-term ownership. For a balanced and conservative long-term investor, an excellent business still needs the right price. If you already own it, there is a good probability that continuing to hold while tracking cash flow, leverage, and acquisition quality is reasonable. If you do not yet own it, I would rather keep it on a high-priority watchlist and wait for the market to offer a thicker margin of safety. Real value investing means building a large position only when a "good company" and a "good price" appear at the same time.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.